• Have a question?
    Open from 8am to 7pm Monday to Friday    Call customer services
    0345 54 32 600


| Print

Enanta Pharmaceuticals (ENTA)

Common Shares
Sell: $15.75|Buy: $19.53|Change: 0.13 (-0.82%)

This share can be held in a Dealing accountStocks and shares ISALifetime ISAJISASIPP

Company profile

Enanta Pharmaceuticals Inc is a biotechnology company that uses a chemistry-based drug discovery approach to develop small-molecule candidates for virology and immunology applications. It focuses on Virology and Immunology. Its active development programs in virology are focused on respiratory syncytial virus, or RSV, and SARS-CoV-2, and Hepatitis B virus. In immunology, the company is engaged in designing and developing potent and selective, oral small molecule inhibitors for the treatment of type 2 inflammatory disease. The company has collaborated with AbbVie, which markets its protease inhibitor paritaprevir, with additional inhibitors in development. The company generates the majority revenue in the form of royalty revenue.

Address

500 Arsenal Street
Watertown
MA
USA
02472

Telephone

+1 617 607-0800

Website

https://www.enanta.com

Sector 

Healthcare

Forecast key dates

NameKey Date
Enanta Pharmaceuticals Inc Annual Report for 20262026-11-19T00:00:00
Enanta Pharmaceuticals Inc Fourth Quarter Earnings Results for 20262026-11-17T00:00:00
Enanta Pharmaceuticals Inc Third Quarter Earnings Results for 20262026-08-11T00:00:00
Enanta Pharmaceuticals Inc Second Quarter Earnings Results for 20262026-05-12T00:00:00
Enanta Pharmaceuticals Inc Annual General Meeting for 20262026-03-13T17:00:00
Enanta Pharmaceuticals Inc First Quarter Earnings Results for 20262026-02-10T00:00:00

Previous key dates

NameKey Date
8th Annual Evercore Healthcare Conference2025-12-03T08:20:00
Enanta Pharmaceuticals Inc Annual Report for 20252025-11-19T00:00:00
Jefferies London Global Healthcare Conference2025-11-18T08:00:00
Enanta Pharmaceuticals Inc Fourth Quarter Earnings Results for 20252025-11-17T00:00:00
Enanta Pharmaceuticals RSVHR Study Results Call2025-09-29T08:30:00
Baird 2025 Global Healthcare Conference2025-09-10T12:15:00
H.C. Wainwright 27th Annual Global Investment Conference:2025-09-09T14:00:00
Cantor Global Healthcare Conference 20252025-09-03T08:35:00
H.C. Wainwright & Co. “HCW@Home” Series2025-08-12T13:00:00
Enanta Pharmaceuticals Inc Third Quarter Earnings Results for 20252025-08-11T00:00:00
Jefferies Global Healthcare Conference2025-06-05T14:00:00
Enanta Pharmaceuticals Inc Second Quarter Earnings Results for 20252025-05-12T00:00:00
H.C. Wainwright 3rd Annual Autoimmune & Inflammatory Disease Virtual Conference2025-03-27T11:00:00
Enanta Pharmaceuticals Inc Annual General Meeting for 20252025-03-13T17:00:00
Enanta Pharmaceuticals Inc First Quarter Earnings Results for 20252025-02-10T00:00:00
43rd Annual J.P. Morgan Healthcare Conference2025-01-15T08:15:00

AJ Bell Management Limited (company number 03948391), AJ Bell Securities Limited (company number 02723420) and AJ Bell Asset Management Limited (company number 09742568) are authorised and regulated by the Financial Conduct Authority. All companies are registered in England and Wales at 4 Exchange Quay, Salford Quays, Manchester M5 3EE. See website for full details. AJ Bell procures the provision of the Morningstar Licensed Tools on an “as is” basis and does not guarantee the performance of or accept liability for the Licensed Tools. To the maximum extent permitted by law, AJ Bell excludes liability for the Licensed Tools, including liability for any failure, interruption, delay or defect in the performance of any Licensed Tool, unless it arises as a direct result of the negligence of AJ Bell.

© Copyright 2026 AJ Bell. All rights reserved.